English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

BriaCell Announces Proposed Effective Date of Share Consolidation
Friday, 3rd January at 5:05 pm
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the "Nasdaq").
The Consolidation is subject to approval by the Toronto Stock Exchange (the "TSX") and is expected to become effective on January 24, 2025 (the "Effective Date"), with the post-Consolidation Common Shares commencing trading on the TSX and the Nasdaq at market open on January 29, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares arising from the Consolidation will be deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. The exercise or conversion price and/or the number of Common Shares issuable under any of the Company's outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
7
Translate
Report
14K Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
9052
Followers
54
Following
109K
Visitors
Follow
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.